The phosphoinositide 3-kinase pathway and therapy resistance in cancer

DSpace/Manakin Repository

The phosphoinositide 3-kinase pathway and therapy resistance in cancer

Citable link to this page

 

 
Title: The phosphoinositide 3-kinase pathway and therapy resistance in cancer
Author: Brown, Kristin K.; Toker, Alex

Note: Order does not necessarily reflect citation order of authors.

Citation: Brown, Kristin K., and Alex Toker. 2015. “The phosphoinositide 3-kinase pathway and therapy resistance in cancer.” F1000Prime Reports 7 (1): 13. doi:10.12703/P7-13. http://dx.doi.org/10.12703/P7-13.
Full Text & Related Files:
Abstract: The phosphoinositide 3-kinase (PI3K)/Akt/mechanistic target of rapamycin (mTOR) signaling network is a master regulator of processes that contribute to tumorigenesis and tumor maintenance. The PI3K pathway also plays a critical role in driving resistance to diverse anti-cancer therapies. This review article focuses on mechanisms by which the PI3K pathway contributes to therapy resistance in cancer, and highlights potential combination therapy strategies to circumvent resistance driven by PI3K signaling. In addition, resistance mechanisms that limit the clinical efficacy of small molecule inhibitors of the PI3K pathway are discussed.
Published Version: doi:10.12703/P7-13
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4335789/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:14351274
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters